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Pictet-Spengler condensation derivatives, known as tetrahydrob-carbolines, have been investigated as agents for treating human diseases, including cancer. The tricyclic tetrahydro-b-carboline ring structure is a motif in both natural and synthetic cytotoxic compounds that can act through multiple mechanisms. 1 Among the tetrahydro-b-carboline compounds that display potent cytotoxicity against numerous cancer cell lines are harman and norharman derivatives, During the last two decades, there has been a tremendous increase in interest in developing more effective treatment strategies for cancer, as traditional chemotherapeutic agents exhibit toxic side effects and induce drug resistance. 8 In particular, numerous small molecules have been discovered that inhibit specific kinases. Some of these compounds have been successfully developed for treatment of cancers, including Gleevec, 9 Iressa, 10 Tarceva, 11 Tykerb, 12 and Sutent. 13 Chemotherapeutic agents are much sought that selectively target tumor cells while having minimal affect on normal cells, as this property decreases the toxicity associated with treatment and assists in understanding genetic networks governing tumors. The rat sarcoma (RAS) oncogenes were discovered over three decades ago with the ability to immortalize mammalian cells. 14 The RAS oncogenes are mutated in 25% of all human tumors, and so are attractive targets for anti-cancer agents. Despite extensive efforts, there are currently no treatments that directly target Ras proteins. Instead, several groups, including ours, have focused on identifying compounds that selectively kill tumor cells expressing oncogenic-RAS genes. Increased lethality in the presence of oncogenic-RAS is termed synthetic lethality. 15 Recently, we identified an inhibitor, which we named MEL24, of the oncoprotein complex Mdm2-MdmX. 18 MEL24 is selectively lethal to immortalized cancer cells and induces cell death by stabilizing the tumor-suppressor p53. Considering that both MEL24 and RSL3 contain the privileged 1,2,3,4-tetrahydro-b-carboline moiety, but quite different substitution patterns, we wondered whether it would be possible to transform the MEL24 scaffold from an Mdm2-MdmX inhibitor to a oncogenic-RAS selective lethal compound, by altering the substitution around the tetrahydro-b-carboline moiety. Towards this end, we designed and synthesized novel tetrahydro-b-carboline derivatives including: (i) 5-(2,9-dihydro-1H-pyrido [3,4-b] indol-1-yl)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (semi-oxidized) and 1,3-dimethyl-5-(9H-pyrido [3,4-b] indol-1-yl) pyrimidine-2,4,6(1H,3H,5H)-trione (fully oxidized) analogs with a barbituric acid moiety at the 1-position (Fig. 1 , compounds 2a/2b); (ii) those with carbon spacers between the tetrahydro-1H-pyrido [3,4-b] indole (tetrahydro-b-carboline) and the barbituric acid moiety, in order to improve their stability and avoid rearrangement and opening of the tricyclic moiety upon protonation of the secondary amine, thus reducing acid lability (Fig. 1, compounds 8 Below, we present the results of these studies, which led to the discovery of a small molecule that (i) exhibits RAS synthetic lethality similar to RSL3, but without acting as a covalent inhibitor, and (ii) induces cell death without activation of caspases. This new compound was discovered through the synthesis of a new series of Pictet-Spengler condensation derivatives, analysis of their structure-activity relationships (SAR), and evaluation of their lethal mechanisms in a panel of seven cancer cell lines.
We were interested in understanding the effect of saturation of the b-carboline nucleus on activity. We started our investigation by oxidizing MEL24 (compound 1, Fig. 1 ) in DMF in the presence of KMnO 4 . We isolated the semi-oxidized compound 2a and the fully oxidized compound 2b in modest yields (25% and 36% yields, respectively) (see Supplementary Scheme 1).
Next, the fully unsaturated b-carbolines 8 and 10 were synthesized in five and six steps, respectively (Scheme 1). Our synthetic strategy (Scheme 1) started with the Pictet-Spengler reaction of tryptophan 3 with dimethoxyglyoxal (60% solution in water) to afford the tetrahydro-b-carboline derivative, which was oxidized with KMnO 4 at room temperature overnight, resulting in acetal 4 (87%, in 2 steps). 19 Compound 4 was methylated in DMF in the presence of NaH and methyl iodide to generate acetal analog 5 in 78% yield. The deprotection of both acetals (4 and 5) in aqueous acetic acid gave aldehydes 6 and 7 in 66% and 75% yield, respectively. The indole nitrogen of aldehyde 6 was protected using di-tert-butyl dicarbonate (Boc) 2 O and 4-(dimethylamino)pyridine (DMAP) to generate compound 7a in quantitative yield (99%). Aldehydes 7 and 7a were coupled with barbituric acid using proline as a catalyst and diludine (Hantzsch Ester) as a source of hydrogen to provide the desired products 8 and 9 in 60% and 55% yields, respectively. Finally, treatment of compound 9 with dilute HCl in dioxane gave the desired compound 10 in quantitative yield (Scheme 1). Previous studies suggested that both the tetrahydro-b-carboline and barbituric acid moieties are important for the activity of MEL 24.
18 Krasnov NaBH 4 ) in two steps, followed by Pictet-Spengler cyclization of the N-protected tryptamine with methyl propiolate in the presence of a catalytic amount of trifluoroacetic acid (TFA) at room temperature, providing tetrahydro-b-carboline 11 in 94% yield (3 steps). Protecting the two nitrogens of 11 was necessary in order to obtain aldehyde 13 in good yield. Thus, aldehyde 13 was prepared in four steps starting from 11: hydrogenolysis of the benzyl group in the presence of Pd/C followed by protection of the two nitrogens of tetrahydro-b-carboline 11 using (Boc) 2 O/DMAP (77% yield, 2 steps). Ester 11 was reduced to the primary alcohol 12a, in the presence of diisobutylaluminum hydride (2.2 equiv of DIBAL-H, 64% yield), which was oxidized to the desired aldehyde 13 using the DessMartin reagent (66% yield) (Scheme 2).
Having aldehyde 13 in hand, we decided to explore the Knoevenagel condensation reaction with barbituric acids, followed by reduction of the double bond in the presence of proline as a catalyst, and the Hantzsch Ester as a source of hydrogen. The desired N-Boc protected products 14 and 16 were isolated in 60% and 55% yields, respectively. Finally, treatment of 14 and 16 with HCl 4.0 N in dioxane under reflux gave the final compounds 15 and 17 in 96% and 92% yields, respectively (Scheme 2). Compounds 22 and 24 (see Supplementary Scheme 2), which have a branched spacer, were successfully prepared in 77% and 75% yields, respectively, using an analogous synthetic route (Scheme 2).
Previously, study of MEL24 analogs revealed that both the tetrahydro-b-carboline and the barbituric acid moieties were necessary to inhibit the Mdm2-MdmX complex. We synthesized 1,2,3,4-tetrahydroisoquinone derivatives without the barbituric acid moiety (Scheme 3) in order to test the notion that this could eliminate the Mdm2-MdmX-targeting activity, but still allow for anti-tumor activity through other mechanisms making use of the tetrahydrob-carboline moiety. Pictet-Spengler cyclization of tryptamine 3 with ethyl glyoxalate provided the ethyl ester tetrahydro-b-carboline 25 in 80% yield, which was reacted with methyl chloroformate in the presence of DIPEA to provide the N-formate 26 in 86% yield. The indole nitrogen of compound 26 was protected by methylation (27) or with Boc (28) in 66% and 88% yields, respectively. Tetrahydro-b-carboline 25 was reacted with chlorobenzylformate/DIPEA or benzyl bromide/K 2 CO 3 , respectively, to provide compounds 29 and 30 in 90% and 86%, respectively. Finally, tetrahydro-b-carboline 31 was prepared by selective protection of the secondary amine using (Boc) 2 O/DMAP followed by methylation of the indole nitrogen in 77% yield (2 steps).
In order to test a variety of tetrahydro-b-carboline analogs, we also synthesized analogs bearing an acetal in the one position instead of an ester (Scheme 4). Once again, Pictet-Spengler cyclization of tryptamine 3 with aqueous glyoxal dimethyl acetal provided the ethyl ester tetrahydro-b-carboline derivative 32 in 92% yield. The secondary amine of 32 was reacted with methylchloroformate in the presence of diisopropyethylamine (DIPEA) followed by Boc protection of the indole nitrogen in the presence of dimethylaminopyridine (DMAP), providing compound 33 in 86% (2 steps). Similarly, compound 34 was obtained in 82% yield by the reaction of the tetrahydro-b-carboline 32 with benzylchloroformate in the presence of diisopropyethylamine (DIPEA). Finally, compound 35 was successfully prepared in 76% yield by reaction of 32 with benzylbromide in the presence of potassium carbonate. All compounds were tested for their Mdm2-MdmX inhibitory activity. 18 As predicted, none of the compounds showed any inhibitory activity (Supplementary Fig. 1 ). In order to determine the potential anti-cancer activity of these Pictet-Spengler condensation derivatives through other mechanisms, all compounds were tested in a 2-fold, 12-point dilution series starting at 20 lg/mL in seven cell lines. The cell lines used represent breast cancer (MCF7), fibrosarcoma (HT-1080), osteosarcoma (U2OS), colon cancer (RKO), lung cancer (H1299), and a pair of engineered isogenic cell lines, BJ-TERT and BJ-TERT/LT/ST/RAS V12 (Table 1) Table 1 ). Among these, compound 27 showed the most potent and Table 1 ).
From testing in the seven cell lines, compound 27 showed the greatest selectivity towards BJ-TERT/LT/ST/RAS V12 and was effective in inducing cell death in six out of seven cell lines. Thus, despite the micromolar potency, we decided to further examine compound 27's mechanism of action.
To examine the selectivity of compound 27 in inducing cell death in the presence of oncogenic-RAS, four engineered isogenic cell lines from BJ foreskin fibroblasts were used. we examined the ability of compound 27 to induce caspase 3/7 activation during cell death (Fig. 2D) . Even at the highest concentrations tested, compound 27 induced cell death in BJ-TERT/LT/ ST/RAS V12 cells, but failed to induced caspase 3/7 activation. On the other hand, MEL24, an established tetrahydro-b-carboline that induces caspase-dependent apoptosis, 18 activated caspase 3/7 in both BJ-TERT and BJ-TERT/LT/ST/RAS V12 ( Supplementary Fig. 3 ).
To study the mechanism of action of compound 27, we tested the ability of several biologically active compounds to suppress the lethality of compound 27, using our recently reported modulatory profiling approach. 25 Supplementary Fig. 5 ). Compound 27, erastin and RSL3 induced increases in DCF fluorescence before cells died, which indicated that ROS are generated in the course of cell death.
Previously, Weiwer et al. 27 reported that ML162, which contains a chloroacetamide moiety, is an oncogenic-RAS selective lethal compound in the BJ cell series (EC 50 (BJ-TERT) = 0.58 lM;
EC 50 (BJ-TERT/LT/ST/RAS V12 ) = 0.025 lM). ML162 was discovered in a manner similar to RSL3 and erastin. Mass spectrometry studies revealed that ML162 reacted in vitro with glutathione (GSH) in the presence of triethylamine, forming an ML162-GSH adduct. Thechloroacetamide moiety is required for this electrophilic activity. The chloro group is a good leaving group, and these compounds may react non-selectively in cells with proteins, DNA and glutathione, leading to undesired off-target effects. 28 We therefore examined whether 27 generates, or is, an electophile, by measuring compound-glutathione adduct formation, signifying the ability of the compound to react non-specifically. MEL24 did not form an adduct with GSH as determined by mass spectrometry, 18 while a known electrophile, phenylisothiocyanate, formed a glutathione adduct under the same reaction conditions ( Supplementary  Fig. 6 ). A 27-glutathione adduct was not observed after 48 h of reaction ( Supplementary Fig. 7 ). Compound 27, unlike ML162, does not contain an electrophilic group and does not act as an electrophile experimentally. This result suggests that compound 27 is likely to be more specific, as it is a non-covalent oncogenic-RAS selective lethal compound. Taken together, these data suggest that compound 27 is selectively lethal to tumorigenic cells and induces non-apoptotic cell death and may be more specific in cells than other electrophilic oncogenic-RAS synthetic lethal compounds.
In conclusion, we have taken advantage of the privileged nature of the tetrahydro-b-carboline scaffold to create a non-electrophilic compound with oncogenic-RAS selective lethality. To do this, we designed and synthesized a novel series of substituted Pictet-Spengler condensation products. These compounds were tested for their lethality against a panel of seven cancer cell lines. Among these compounds, compound 27 showed a unique selectivity towards tumorigenic versus non-tumorigenic cells. Further investigations revealed that this compound exhibits (1) synthetic lethality with oncogenic-RAS and (2) caspase-independent cell death. Based on these data, we suggest that compound 27 induces caspase-independent cell death selectively in cancerous cells. These studies have revealed a potentially useful probe for studying caspase-independent ferroptotic cell death and oncogenic-RAS signaling, and have highlighted the utility of the tetrahydro-carboline scaffold.
